secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001193125-23-156584
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin stockholders approve 14M share increase to equity plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders elected all 11 director nominees; each received substantial majority support.
- Advisory vote on named executive officer compensation passed with 129.8M for, 24.5M against.
- Amendment to 2017 Equity Incentive Plan adding 14M shares approved by shareholders.
- KPMG LLP ratified as independent auditor for fiscal 2023; advisory vote on compensation frequency set to 1 year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523156584/0001193125-23-156584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312523156584/d476134d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-156584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer